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Graphene, a single-atom-thick carbon nanosheet, has attracted great interest as a prom-
ising nanomaterial for a variety of bioapplications because of its extraordinary properties.
However, the potential for widespread human exposure raises safety concerns about
graphene and its derivatives, referred to as graphene-family nanomaterials. This review
summarizes recent findings on the toxicological effects and the potential toxicity mecha-
nisms of graphene-family nanomaterials in bacteria, mammalian cells, and animal
models. Graphene, graphene oxide, and reduced graphene oxide elicit toxic effects both
in vitro and in vivo, whereas surface modifications can significantly reduce their toxic in-
teractions with living systems. Standardization of terminology and the fabrication
methods of graphene-family nanomaterials are warranted for further investigations
designed to decrease their adverse effects and explore their biomedical applications.
Copyright ª 2014, Food and Drug Administration, Taiwan. Published by Elsevier Taiwan
LLC.Open access under CC BY-NC-ND license. 1. Introduction
Advancements in the field of nanotechnology have the po-
tential for improving diagnostic, therapeutic, and preventive
medical products, as well as in applications for food pack-
aging, processing, and preservation. The United States Food
and Drug Administration has already approved some
nanotechnology-based products and expects a significant in-
crease in the use of nanomaterials in drugs, devices, biologics,
cosmetics, and food [1]. However, the rapid development andre those of the authors
and Molecular Toxicolog
v (X. Guo).
ministration, Taiwan. Publicommercialization of nanoscale products in recent years have
increased the possibility of human exposure to engineered
nanomaterials through four distinct entry routes: inhalation,
ingestion, dermal penetration, and injection or implantation
[2,3]. For safe applications of the nanoscale products, it is
essential that thorough safety assessments be conducted in
order to protect human health and the environment [4].
Recently, a novel promising nanomaterial, monolayer gra-
phene, has attracted much interest. Andre Geim and Kon-
stantin Novoselov first described graphene in 2004 as
monocrystalline graphitic films [5]. Both were awarded theand do not necessarily reflect those of the US Food and Drug
y, National Center for Toxicological Research, 3900 NCTR Road,
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ments regarding the two-dimensional material graphene”.
Graphene, one of the carbon nanomaterial allotropes, is a
single-atom-thick, two-dimensional sheet having sp2-hy-
bridized carbon atoms arranged hexagonally. It is the thinnest
possible configuration of carbon molecules, and is a basic
building block for other graphitic materials such as graphite,
large fullerenes, and carbon nanotubes (CNTs) [6]. Graphene
has unique physicochemical properties including a high sur-
face area, extraordinary electrical and thermal conductivity,
and strong mechanical strength [6,7]. The excellent electronic
transport properties and high surface-to-volume ratios endow
it with unique mechanical and rheological properties, and
resistance to degradation [8]. The two active parts, surfaces
and edges, facilitate graphene attaching to biological mole-
cules and adhering to cells [9].
Since 2004, graphene has become a “superstar” in the field
of nanotechnology. Graphene is a promising nanoplatform for
numerous applications including in nanoelectronics and en-
ergy technology (supercapacitors, batteries, and composites)
as sensors, and for biomedical applications (drug/gene de-
livery, biosensors, cell and tumor imaging, adsorption of en-
zymes, and cancer photothermal therapy) [10e15]. These
widespread applications have attracted interest in the
manufacturing of graphene and its derivatives, referred to as
graphene-family nanomaterials (GFNs). GFNs include single-
or few-layer graphene, graphene nanosheets, graphene rib-
bons, graphene oxide (GO), and reduced graphene oxide (rGO)
[16]. Subsequent development of covalently and non-
covalently functionalized GFNs improved their biocompati-
bility, stability, and reduced their toxic side effects in the
physiological environment [17e19].
Reports indicate that the market projections for graphene-
based products will reach $675 million by 2020 [20]. This re-
view describes the most recent reports on the toxicological
activity of GFNs both in vitro and in vivo. Also discussed are the
effects of GFN functionalization on diminishing their toxic
interaction with cells, and the potential mechanisms for
GFNs-induced toxicity. Thematerial properties relevant to the
biological effects and the applications of GFNs in the field of
drug delivery and food preparation are also covered in this
article.2. The properties and bioapplications of
GFNs
GFNs vary in shape, size, surface area, layer number, lateral
dimensions, surface chemistry, stiffness, defect density or
quality of the individual graphene sheets, and purity; and all
these properties significantly influence the interaction of
GFNs with biological systems [16]. Generally, GFNs with small
size, sharp edges, and rough surfaces easily internalize into
the cell as compared to larger, smooth GFNs. GFNs, particu-
larly monolayer graphene, have the theoretical maximum
surface area because every atom lies on the surface, providing
an extremely high capacity for drug delivery. The specific
surface area and bending stiffness depend on the number of
layers. For biological molecules, the more layers of GFNs, the
lower the adsorptive capacity. The lateral dimensions of GFNs,with a range of 10 nm to >100 mm, affect cell uptake mode-of-
action, renal clearance, bloodebrain barrier transport, and
many other biological interactions [21,22]. The surface
chemistry varies greatly among the members of GFNs even
before any surface modification; it determines their hydro-
philicity or hydrophobicity, stability, and dispersibility in
physiological conditions [16]. Furthermore, because graphene
can be synthesized by various methods, e.g., mechanical or
chemical exfoliation of intercalated bulk graphite [6,23], it is
inevitable that GFNs contain some impurities such as chem-
ical additives or residual intercalants, including nitrate, sul-
fate, and peroxide [16]. Compared to as-made GO, highly
purified GO produces negligible negative effects in vitro and
in vivo [24], indicating a need to consider the impurities for the
biological effects studies.3. Applications in drug delivery and food
Due to graphene’s unique properties, there has been
increasing interest in using graphene and its derivatives for
drug delivery [19]. The planar structure and ultra-high surface
area (2600 m2/g) of graphene facilitate molecular loading and
bioconjugation [25]. GFNs, specifically GO and graphene, have
been evaluated as novel nanocarriers for a variety of thera-
nostic applications, including the delivery of conventional
drugs, because their use may alleviate problems due to
multidrug resistance and nonspecific targeting [26,27]. Previ-
ous in vitro and in vivo studies have confirmed that GO is highly
efficient in the targeted delivery of the anticancer drugs,
doxorubicin and SN38 (a camptothecin analogue), and it is a
promising platform for cancer therapy involving insoluble
drugs [28,29]. Subsequently, development of various func-
tionalized GFNs has improved the biocompatibility, solubility,
and drug delivery efficiency [30e34]. For example, transferrin-
conjugated polyethylene glycol (PEG)-GO displayed greater
intracellular delivery efficiency and stronger cytotoxicity
against C6 glioma cells [33], and a doxorubicin-loaded target-
ing peptide-modified mesoporous silica-coated graphene
nanosheet provided synergistic chemo-photothermal tar-
geted therapy for gliomas [34].
Recently, development of a dual-targeted (magnetic and
biological) drug delivery system has improved efficiency. Tri-
ple functionalized GO-doxorubicin, encapsulated by Fe3O4 and
folic acid-conjugated chitosan, exhibited high loading effi-
ciency and targeted drug delivery to the tumor area [35]. In
addition, delivery ofmore than one anticancer drug by GO also
has been reported [14]. Controlled loading of both doxorubicin
and camptothecin onto folic acid-conjugated GO via pep
stacking and hydrophobic interactions resulted in both target
specificity and much higher cytotoxicity to MCF-7 cells than
conjugated GO loaded with either drug alone [14]. The most
recent in vivo studies also demonstrate an enhanced anti-
cancer effect of functionalized GFNs as a drug delivery system.
Transferrin conjugated PEG-GO-doxorubicin delayed tumor
volume expansion and increased the survival of a C6 glioma-
bearing rat model [33]. Intravenous injection of 40 mg/kg
doxorubicin loaded on cholesteryl hyaluronic acid modified
rGO in tumor-bearing mice exhibited a higher loading capac-
ity, increased colloidal stability under physiological
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tumors when compared to rGO/doxorubicin [36]. A zebrafish
model demonstrated that a GO/NPecurcumin complex was
excreted quickly from the zebrafish body and had nearly no
influence on the development of zebrafish from embryos (the
stage of 12 cells) to larvae (age, 4 days), suggesting the safe
bioapplication of graphene-based therapeutic modalities [37].
Applications of GFNs related to food include their use for
food packaging, water purification, and sensors for detecting
contamination. Graphene nanoplates can form heat resistant
and high barrier nanocomposites that prevent the migration
of oxygen, CO2, and water vapor, and thus have promising
applications in food packaging [38]. rGO-Ag coated carbon
foam was reported to kill pathogenic microbes in drinking
water successfully with the aid of a 1.5 V battery [39]. GFN-
based sensors have proven effective for detecting contami-
nation in food and water. For instance, a disposable Ag-
graphene sensor can selectively adsorb polar antibiotics in
water through weak pep interactions between graphene and
antibiotics [40]. A rGO-modified screen-printed carbon elec-
trode disposable sensorwas capable of detecting lead in foods,
tap water, juice, and tea samples with a detection limit as low
as 1 ppb [41]. Based on these reports, future expectations are
that more GFN-based nanocomposites will be developed to
improve the speed and sensitivity of detecting contamination
in food and water samples.4. Toxicity of GFNs
Reports indicate that GFNs exert measurable cytotoxicity in
both in vitro and in vivo studies in various types of bacteria,
mammalian cells, and animal models. Most published studies
have evaluated GO and rGO due to their better solubility/dis-
persibility/stability in water and under physiological condi-
tions compared to other GFNs.
4.1. Toxicity in bacteria
Recent studies have investigated GFNs toxicity in both bac-
teria and fungi. Graphene effectively inhibited the growth of
Gram-negative Escherichia coli and Gram-positive Bacillus sub-
tilis at a concentration of 1 mg/mL [42]. Two water dispersible
graphene derivatives, GO and rGO nanosheets, inhibited the
growth of E. coli with minimal cytotoxicity [43]. In the colony-
forming assay, more than 90% of the bacteria lost viability
following a 2-hour incubation of E. coliwith 85 mg/mL of GO or
rGO. Transmission electronmicroscopy (TEM) revealed severe
cell membrane damage and cytoplasm leakage, which might
be caused by either oxidative stress or physical disruption [43].
Both GO and rGO nanowalls were bactericidal to E. coli as well
as Gram-positive Staphylococcus aureus strains when deposited
on a stainless steel substrate, with rGO nanowalls being more
toxic to both bacteria than the unreduced GO nanowalls. A
better charge transfer between bacteria and the sharper edges
rGO nanowalls correlated with the severe antibacterial effect.
Cell membrane damage caused by direct contact between the
bacteria and the extremely sharp edges of the nanowalls is
thought to be an effective mechanism for its antibacterial
activity [44]. Later, the antimicrobial activity of four types ofgraphene-based materials (graphite, graphite oxide, GO, and
rGO) toward E. coli was studied using the colony counting
method. The results indicated that GO had the highest anti-
bacterial activity, followed in decreasing order by rGO,
graphite, and graphite oxide [45]. This study proposed a three-
step antimicrobial mechanism for GFNs, which was similar to
the cytotoxicitymechanism proposed for CNTs. That is, initial
cell deposition on GFNs, significant membrane stress caused
by direct contact with sharp edges, and subsequent superox-
ide anion-independent oxidation [45]. Other studies have
observed the oxidative stress-mediated antibacterial activity
of GO and rGO in additional bacterial strains, e.g., Pseudomonas
aeruginosa [46].
Recently, Tu et al. [47] discovered a novel mechanism for
graphene’s cytotoxicity and antibacterial activities, destruc-
tive extraction of phospholipids from E. coli membranes.
After a 2.5-hour incubation of E. coli with 100 mg/mL GO
nanosheets, three stages of cell damage were observed by
TEM. In Stage I (initial morphology), the cells were tolerant to
GO for a short period of time; in Stage II, the cell membranes
partially lost integrity, with some presenting a lower surface
phospholipid density; and in Stage III, the cell membranes
were severely damaged and some were even entirely missing
their cytoplasm [47]. Subsequent molecular dynamic simu-
lation similarly observed three distinguishable modes thus
confirming these results. Firstly, the swing mode: the gra-
phene nanosheet swung back and forth around the
restrained atom for tens to hundreds of nanoseconds. Sec-
ondly, the insertion mode: the edge of the nanosheet entered
and cut into the cell membranes in a few nanoseconds due to
robust van der Waals attractions from the membrane lipids
and hydrophobic interactions. Thirdly, the extraction mode:
the nanosheet drew the phopholipid molecules vigorously
from the lipid bilayers onto its surface. These observations
suggest that both graphene insertion/cutting and destructive
lipid extraction lead to serious membrane stress, thus
decreasing cell viability [47].
Besides the antibacterial effects of the GFNs, antifungal
activity has been reported for rGO nanosheets. A fungal cul-
ture was placed at the center of a Petri dish containing potato
dextrose agar and 0e500 mg/mL rGO nanosheets [48]. A 7-day
incubation completely inhibited all the mycelia growth at
the highest concentration of rGO, and direct contact was
proposed as the mechanism for the activity. By contrast, GO
exhibited no antifungal effect against Candida albicans or
Candida tropicalis. In addition, GOeAg nanocomposites used as
a carrier of silver nanoparticles had prolonged antifungal ac-
tivity due to the controlled release of silver ions [49]. Moreover,
GOeAg nanocomposites with an optimal ratio of silver
nanoparticles to GO also displayed enhanced, strong anti-
bacterial activities against E. coli and S. aureus strains with
species-specific mechanisms. GOeAg nanocomposite dis-
rupted E. coli bacterial wall integrity, whereas it greatly
inhibited S. aureus cell division [50].
Recently, ever more graphene-based nanocomposites,
such as GOeAg, GOeTiO2eAg, poly-L-lysine/rGO/copper
nanoparticles, and poly(N-vinylcarbazole)/graphene, have
been developed for antimicrobial applications due to their
high stability, permeability, and enhanced antimicrobial ac-
tivities [42,50e52]. However, other studies have questioned
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and suggest GO can act as a scaffold for E. coli bacterial
attachment, proliferation, and biofilm formation [53]. These
conflicting results encourage additional investigations on the
effects of GFNs on microorganisms. However, because GFNs
generally have demonstrated bacterial toxicity and relatively
low cytotoxicity, it has been suggested that these materials
might have applications in antimicrobial products, similar to
the most widely used antimicrobial nanoscale substance, sil-
ver nanoparticles [54].
4.2. In vitro mammalian cell toxicity
Initial screening of new materials for an in vitro toxicity
assessment commonly uses a variety of cell lines. Data from
the literature suggest that GFNs exposure may result in cyto-
toxicity and/or genotoxicity in mammalian cells.
4.2.1. Graphene
A comparative study measuring mitochondrial toxicity and
cell membrane integrity in neuronal PC12 cells using the 3-
(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
(MTT) assay and the lactase dehydrogenase (LDH) release
assay suggested that the biological activities of graphene and
single-wall CNTs (SWCNT) were shape-dependent [55]. After
a 24-hour exposure, the metabolic activity of PC12 cells
decreased in a dose-dependent manner, with graphene pro-
ducing higher toxicity at low concentrations and lower
toxicity at high concentrations than SWCNT. The highest
concentration of graphene in this study (100 mg/mL) signifi-
cantly increased LDH release and the generation of reactive
oxygen species (ROS). In addition, caspase 3 activation indi-
cated that graphene induced a time-dependent increase in
apoptosis at a concentration of 10 mg/mL. Yuan et al. [56]
compared the potential cytotoxicity of graphene and
SWCNT on the human hepatoma HepG2 cell line at the
proteome level. These researchers used the isobaric-tagged
relative and absolute quantification-coupled two-dimen-
sional liquid chromatographyetandem mass spectrometry
(iTRAQ-2D LC-MS/MS) approach to characterize graphene
and SWCNT exposed HepG2 cellular functions. Overall, 1 mg/
mL of both nanomaterials resulted in differential expression
of 37 proteins involved in metabolic pathways, redox regu-
lation, cytoskeleton formation, and cell growth, with gra-
phene resulting in more moderate variations in protein
levels. An interesting finding was that graphene and SWCNT
produced different patterns in the expression levels of
calcium-binding proteins, indicating that they had different
modes of action [56].
Later, pristine graphene was also found to increase ROS
and apoptosis in murine RAW 264.7 macrophages, an impor-
tant effector cell of the innate immune system [57,58]. The
proposed underlying mechanisms were the depletion of
mitochondrial membrane potential (MMP) and ROS-triggered
apoptosis by the activation of the mitochondrial pathway.
This study found that both mitogen-activated protein kinases
and transforming growth factor-b (TGF-b) related signaling
pathways were involved in the toxicity of pristine graphene-
treated macrophages. The expression of three major phos-
phorylated kinases (c-Jun N-terminal kinase, p38, andextracellular signal-regulated kinase), two proapoptotic
members of the Bcl-2 protein family (Bim and Bax), and TGF-b
were significantly upregulated [57].
Human glioblastoma U87 and U118 cells were used to
examine the influence of graphene platelets on cell
morphology, mortality, viability, membrane integrity, and the
type of cell death [9]. Graphene platelets had a strong ten-
dency to localize close to the cells, but not enter into the cells.
At a concentration of 100 mg/mL, a 24-hour treatment caused
about 50% cell death and loss of membrane integrity and
apoptosis. Layered graphene platelets (1e10 layers) at con-
centrations 5 mg/cm2 also significantly increased the release
of LDH in immortalized human acute monocytic leukemia
cells (THP-1), indicating loss of membrane integrity. The
depletion of reduced glutathione and higher expression of a
panel of cytokines [e.g., monocyte chemotactic protein-1,
interleukin (IL)-1, macrophage inflammatory protein-1R, and
IL-1b] were also observed after graphene platelet exposure
[59].
4.2.2. GO
GO is the most extensively investigated member of GFNs in
in vitro toxicity studies. Although the first comprehensive
study on the toxicity of GO observed neither obvious cellular
uptake nor obvious effects on the morphology, viability,
mortality, and membrane integrity in adenocarcinomic
human alveolar basal epithelial (A549) cells, GO exposure was
able to induce oxidative stress at a concentration as low as
10 mg/mL [60]. This, however, is one of the few reports of a
negative cytotoxic response for GO in mammalian cells. A few
months later, using the same cell line, Hu et al. [61] reported
that GO produced concentration-dependent cytotoxicity,
which could be largely attenuated by incubation with 10%
fetal bovine serum, due to GO’s extremely high protein
adsorption ability. Subsequently, the toxicity, genotoxicity,
and the potential mechanisms of GO have been reported in a
variety of human and animal cell lines, including immortal-
ized and normal cell lines, immune cells, stem cells, and blood
components.
In studies using immortalized cells, the toxicity of GO has
been reported in the HepG2 cell line. Lammel et al. [62]
evaluated the cytotoxicity of 1e16 mg/mL GO by four assays
[5-carboxyfluorescein diacetate-acetoxymethyl ester (CFDA-
AM), alamar blue assay, neutral red uptake assay, and fluo-
rescamine assay]. GO caused a dose-dependent decrease in
fluorescence intensity starting at 4 mg/mL in the CFDA-AM
assay, indicating plasma membrane damage; and loss of
plasma membrane structural integrity was associated with a
strong physical interaction of GO with the phospholipid
bilayer [62]. TEM and scanning electron micrographs
demonstrated that GO was able to penetrate through the
plasma membrane, resulting in altered cell morphology and
an augmented number of apoptotic cells. In addition, the
parallel alterations of elevated ROS at concentration as low as
1 mg/mL and dose-related depletion of the MMP suggest that
impaired mitochondrial function may lead to intracellular
ROS formation. Among the modes of action assessed, the
authors concluded that plasma membrane damage and
oxidative stress play crucial roles in GO-induced cytotoxicity
[62]. Yuan et al. [63] evaluated the cytotoxicity of GO and
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[56] to characterize cellular function. Similar to their previous
study, 1 mg/mL of both GO and oxidized SWCNTs led to
altered protein expression involved in metabolic pathways,
redox regulation, cytoskeleton formation, and cell growth,
with GO inducing much lower changes in expression in
comparison to oxidized SWCNTs [63]. Moreover, a minor
reduction in proliferation rate, slightly perturbed cell cycle,
and elevated intracellular ROS levels also were observed in
GO-treated cells, suggesting that GO has less cytotoxicity in
HepG2 cells. The cytotoxicities of GO-1 and its repeated
KMnO4eH2SO4 oxidation products, GO-2 and GO-3, have been
compared in HeLa cells using the MTT assay. The average
lateral sizes of GO-1, GO-2, and GO-3 were 205.8 nm,
146.8 nm, and 33.78 nm, respectively [64]. GO-1 produced
significant cytotoxicity at concentrations of 20e100 mg/mL,
whereas GO-2 and GO-3 exhibited significantly higher
viability with higher cellular uptake in HeLa cells, suggesting
that the larger sized GO caused greater damage to the cell
membrane as compared to the smaller sized GOs. Another
study also reported a dose-dependent toxicity of GO in HeLa
cells, with a lower cell uptake ratio compared to CNT and
nanodiamond [65]. GO cytotoxicity also was reported for
human neuroblastoma SH-SY5Y cells at concentrations
80 mg/mL [66].
GO-induced cytotoxicity, genotoxicity, and oxidative stress
have been investigated in normal human lung fibroblast cells
[67]. The MTT assay indicated a significant decrease in cell
viability and an increase in toxicity following a prolonged
treatment time, as well as an apoptotic effect of GO at a con-
centration of 100 mg/mL. Furthermore, for the first time, the
genotoxicity of GO was assessed using the Comet assay. DNA
damage, as measured by increased tail length and the per-
centage of DNA in the tail, were found for all the tested con-
centrations including 1 mg/mL. It is worth noting that 1 mg/mL
GO caused no obvious decrease in cell viability or increase in
cellular apoptosis, suggesting that genotoxicity assays may
serve as amore sensitive and representative way to detect the
toxicity of GO in mammalian cells [67]. The accumulation of
ROS, the decreased level of cellular superoxide dismutase, and
the reversal in cytotoxicity by the addition of the antioxidant
N-acetylcysteine all support an oxidative stress mechanism
for GO-induced toxicity in human lung fibroblast cells. A novel
finding from this study was that the surface charge of GO and
GO derivatives changed their aggregation status as well as
their ability to be internalized. It was proposed by the authors
that the lower the positive surface charge of GO, the milder
the toxic effect of GO on cells. Therefore, it may be useful for
clinical applications that new ways are found to attenuate GO
toxicity by decreasing its electrical surface charge. Another
normal fibroblast cell line, human dermal fibroblast, was
cultured with 5e100 mg/mL of GO for 1e5 days [68]. Doses of
GO <20 mg/mL had little toxicity to human dermal fibroblast
cells, whereas doses 50 mg/mL exhibited obvious cytotox-
icity, such as decreased cell survival by cell counts, reduced
adhesive ability, and increased cell apoptosis. TEM revealed
that GO was indeed internalized by the cells and subcellularly
localized to the lysosomes, mitochondria, endoplasm, and
even the cell nucleus in a time- and dose-dependent manner
[68].GO toxicity also has been described in BEAS-2B human lung
cells and the HBI.F3 human neural stem cell line. In BEAS-2B
cells, significant concentration- and time-dependent de-
creases in cell viability were observed at concentrations of
10e100 mg/mL by the MTT assay, and both early and late
apoptotic cells were increased when compared to the control
[69]. HBI.F3 cell viability was decreased with increasing GO
nanopellet concentration (25e200 mg/mL), which was verified
by both the MTT assay and differential pulse voltammetry, a
microscopic imaging tool [70].
In comparison to previous studies, GO had minimal
toxicity in spontaneously arising human retinal pigment
epithelium (ARPE-19) cells. Toxicity was measured by cell
morphology, viability, membrane integrity, and apoptosis
using various approaches, including optical micrography, the
CCK-8 assay, LDH assay, and apoptosis assay [71]. The cells
were found to be in a good condition after the addition of up to
100 mg/mL GO for 72 hours, but the cell morphology exhibited
some alterations following 7 days’ culture with GO. At all
concentrations, <8% of cells released LDH, indicating little
damage to the cell membrane. This study suggests that GO
has good biocompatibility with retinal pigment epithelium
cells, producing only slight effects on cell viability and
morphology [71].
The ability of GO to induce immunotoxicity and potential
mechanisms for this toxicity have also been studied [72e74].
Three types of immune cells, macrophages, dendritic cells,
and T-lymphocytes, were isolated from healthy donor blood
and treated with up to 100 mg/mL of GO. The levels of three
cytokines (tumor necrosis factor-a, IL-1b, and IL-6), measured
by the enzyme-linked immunosorbent assay, were increased
in dendritic cells with increasing GO doses. Exposure to GO
also induced apoptosis in T-lymphocytes in a dose-
dependent manner as measured by the Annexin Vþ/PIþ
assay. Macrophages easily ingested GO and formed black
dense aggregates within the cells; GO coated with poly-
vinylpyrrolidone exhibited improved immunological
biocompatibility in vitro [73]. Chen et al. [74] found that
treatment of RAW264.7 macrophages with GO resulted in
autophagic vacuoles and activation of autophagic marker
proteins. Molecular analysis demonstrated the toll-like re-
ceptor (TLR) signaling cascades and the ensuing cytokine
pathway were involved in the GO-induced inflammatory
response [74]. The evidence indicated that interaction of GO
with TLR4 was probably responsible for GO-induced macro-
phage necrosis. Inhibition of the TLR4 signaling with a se-
lective TLR4 inhibitor (CLI-095) greatly reduced GO-induced
cell death [72].
As GFNsmay enter blood during drug delivery applications,
it is important to assess their haemocompatibility and toxicity
to blood components. Liao et al. [75] compared the cytotoxicity
of graphene sheets and GO in human erythrocytes and CRL-
2522 adherent human skin fibroblasts. The results indicated
that the graphene and GO toxicity was environment-
dependent, e.g., whether aggregation occurred and the mode
of interaction with cells. By measuring the efflux of hemo-
globin from suspended red blood cells, the authors observed
that the smallest sized GO had the greatest hemolytic activity,
whereas aggregated graphene exhibited the lowest hemolytic
activity. Similarly, compacted graphene sheets induced more
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measured by the water-soluble tetrazolium salt, trypan blue
exclusion, and ROS assays [75]. Moreover, this study suggested
that the MTT assay might lead to a false-positive result by
overestimating cell viability. This is because GO reacts with
the MTT reagent and forms purple formazan. In blood plate-
lets, atom-thin GO sheets elicited a strong aggregate response
through the activation of Src kinases and the release of cal-
cium from intracellular stores [76].
4.2.3. rGO
In an early rGO study with three cell types (PC12 cells,
oligodendroglia cells, and osteoblasts), rGO films were found
to be more biocompatible as compared to SWCNT [77].
Recently, the size- and concentration-dependent cytotoxicity
and genotoxicity of rGO and GO nanoplatelets has been
studied in fresh human mesenchymal stem cells (hMSCs)
isolated from umbilical cord blood. Toxicity was measured
using the fluorescein diacetate cell viability assay, RNA
efflux, and the Comet and chromosomal aberration assays
[78]. The fluorescein diacetate test showed significant cyto-
toxic effects for rGO with an average lateral dimension of
11 nm (the smallest rGO in this study), even at the lowest
concentration of 1 mg/mL and after a 1-hour exposure. rGOs
with an average lateral dimension of 3.8 mm, the largest-
sized-rGO used in this study, exhibited lower cytotoxicity as
compared to rGOs with average lateral dimensions of 91 nm
and 418 nm [78]. Assays for RNA efflux from cells, an indirect
indicator of membrane damage, determined there was a
consistent size- and concentration-dependent response in
rGO-treated hMSCs. The smaller-sized-rGO induced higher
RNA effluxes than did the larger-sized-rGO sheets. Moreover,
rGOs generated 13e26-fold higher levels of ROS when
compared to the control. This suggests that oxidative stress is
one of the mechanisms involved in rGO cytotoxicity. In the
genotoxicity study, 1-hour’s exposure to rGOs with average
lateral dimensions of 11 nm and 91 nm initiated significant
increases in DNA damage and chromosomal aberration fre-
quency at concentrations as low as 0.1 mg/mL and 1.0 mg/mL,
respectively. These concentrations were 10 times lower than
the threshold concentration observed in the cell viability test.
The two larger-sized rGO sheets induced only slight DNA
fragmentation at the highest concentration of 100 mg/mL and
after a longer exposure time of 24 hours [78]. These results
suggest that the interaction of rGOs with hMSCs, and prob-
ably other cells, strongly depends on their lateral size. The
most likely mechanisms involved in rGO cytotoxicity are
oxidative stress and direct contact of the sharp edges with
the cells. The latter may subsequently induce genotoxicity in
cells through interaction of the penetrated nanosheets with
the nucleus of the cells [78].
rGO induced significantly higher cytotoxicity than GO in
A549 cells. Using the MTT assay, Hu et al. [43] found that rGO
nanosheets with a thickness of 4.6 mm reduced cell viability to
47% and 15% at concentrations of 20 mg/mL and 85 mg/mL,
respectively. Green synthesized rGO, namely bacterially rGO,
also induced higher levels of cytotoxicity, ROS, and loss of
membrane integrity in MCF-7 cells as compared to GO [79].
Incubation of MCF-7 cells with both bacterially rGO or GO at
doses above 60 mg/mL produced marked cytotoxic effects,including decreased cell viability, increased ROS generation,
and release of LDH [79].
4.2.4. Functionalized graphene-family nanomaterials
Most GFNs tend to aggregate in physiological solutions due to
electrostatic charges and nonspecific binding to protein [19].
Therefore, development of functionalized GFNs has improved
their solubility and biocompatibility, and reduced cytotoxicity
and genotoxicity. Two main strategies, covalent conjugation
and noncovalent physisorption, are commonly used for sur-
facemodification of GFNs to build desired functionalized GFNs
[19,26]. Polymers or molecules used for covalent GFN modifi-
cation include many types of aliphatic and aromatic amines,
amino acids, amine terminated biomolecules, silanes, and
enzymes [26]. Examples of GFN modifiers include PEG [29],
polyethylenimine (PEI) [80], polyvinyl alcohol [81], and chito-
san [82,83]. Noncovalentmethods of functionalization employ
hydrophobic interaction, pep interaction, van der Waals
forces, and electrostatic binding [19,26], and they appear to be
more versatile than covalent methods. Reports of both cova-
lent conjugation and noncovalent physisorption techniques
indicate distinct decreases in GFN’s toxic side effects.
Sasidharan et al. [58,84] compared interactions of pristine
graphene and functionalized graphene with monkey renal
epithelial cells, murine RAW 264.7 macrophages, and primary
human blood components. In the monkey cells, internaliza-
tion of functionalized graphene into the cells did not produce
any obvious short-term toxicity, whereas pristine graphene
accumulated on the cell membrane leading to ROS-mediated
apoptosis [84]. Similar to this observation, pristine graphene
was mainly retained on the surface of RAW 264.7 macro-
phages, resulting in significantly reduced cell viability and the
formation of intracellular ROS in w24.2% of cells at a con-
centration of 75 mg/mL. By contrast, only 4% of functionalized
graphene-treated cells exhibited ROS generation with no toxic
effect at concentrations of up to 75 mg/mL and even with very
high intracellular uptake. Furthermore, treatment of periph-
eral bloodmononuclear cells with pristine graphene produced
higher expression of IL-8 and IL-6 than treatment with func-
tionalized graphene, indicating a higher inflammatory po-
tential for pristine graphene. These results suggest that
surface functionalization of pristine graphene can prevent
much of its toxicity [58].
To determine the effects of functionalized GFNs on blood
component toxicity, the effect of amine-modified graphene on
platelet reactivity has been evaluated [85]. Unlike GO and rGO,
which prompted a strong aggregatory response in platelets,
amine-modified graphene had no stimulatory effect on
human platelets. Intravenous administration of amine-
modified graphene also did not potentiate the lysis of eryth-
rocytes or pulmonary thromboembolism in mice. These re-
sults indicate that amine-modified graphene is potentially
safe for in vivo biomedical applications [85]. Comparison of GO
and PEGylated nano-GO interactions with human serum
components revealed that GO adsorbed numerous serum
proteins and strongly induced complement C3 cleavage thus
forming C3a/C3a(des-Arg), an anaphylatoxin involved in local
inflammatory responses. By comparison, PEGylated GO had
significantly lower levels of both serum protein binding and
complement C3 activation [86]. Interestingly, PEGylated nano-
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serum proteins, and four of them were immune-related fac-
tors, including C3a/C3a(des-Arg). These findings suggest that
PEGylated nano-GO may serve as an immune response
modulator to eliminate C3a/C3a(des-Arg) resulting from other
nanomaterials [86].
Functionalization, however, does not always eliminate the
toxicity of GFNs. The reported IC50 of noncovalent PEGylated
nanosized rGO was about 80e85 mg/mL in both the human
breast cancer cell line MCF-7 and human glioblastoma U87MG
cells [87]. Carboxyl graphene, having a high carboxyl ratio and
additional ethanoic acid groups (eOeCH2eCOOH) on sp
3-hy-
bridized carbon on the basal plane, was found to cause a dose-
dependent decrease in fluorescence intensity starting from
4 mg/mL in the CFDA-AM assay, indicating plasma membrane
damage. In addition, carboxyl graphene increased ROS pro-
duction and produced a dose-related depletion of MMP in
HepG2 cells [62].
TheadverseeffectsofGOnanoribbonswater-solubilizedwith
PEG-DSPE (1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-amino-PEG; O-GNR-PEG-DSPE) have been assessed using
different toxicity assays (including the alamar blue, neutral red,
LDH release, trypan blue, and clonogenic assays) in four repre-
sentative cell lines [HeLa,MCF-7, NIH 3T3mouse fibroblasts, and
Sloan Kettering breast cancer cells (SKBR3)] [88]. Test doses
ranged from 10 mg/mL to 400 mg/mL, and all cells experienced
dose- and time-dependent reductions in cell viability. HeLa cells
displayed the highest cellular uptake and cytotoxicity as deter-
mined by the cellular metabolism, lysosomal integrity, LDH
release, and cell proliferation assays. Significant cell death
(5e25%, depending on the time point and the assay) for HeLa
cells occurred at concentrations 10 mg/mL. By contrast, about
78% of cells were still viable at the highest concentration of
400 mg/mL in SKBR3 and MCF-7 cells, indicating that water-
solubilized O-GNR-PEG-DSPE has a heterogenous cell-specific
cytotoxicity [88].
The cytotoxicity of three derivatives of GO, PEI-GO, PEG-
GO, and lactobionic acid-polyethylene glycol (LA-PEG) func-
tionalized GO (LA-PEG-GO), was compared in human lung
fibroblast cells: the order of cytotoxicity was PEG-GO < LA-
PEG-GO < GO < PEI-GO [67]. The Comet assay indicated that
PEG and LA-PEG modified GOs were less genotoxic, and that
PEI-modified GO damaged DNA to a similar extent as un-
modified GO.
4.3. In vivo toxicity
Information on the in vivo toxicity of GFNs is essential if they
are to be used for drug delivery. The in vivo toxicity of GO has
been studied in Kunming mice [68]. No toxicity was detected
in mice exposed intravenously to GO at a low (0.1 mg) and
middle (0.25 mg) dose, whereas a high dose of GO (0.4 mg)
resulted in chronic toxicity. Four of nine mice died from suf-
focation 1e7 days after injection due to blockage of the major
airways by GO conglomeration. GO accumulation was detec-
ted primarily in the lungs, liver, and spleen. For the surviving
mice, obvious chronic toxicity occurred mainly in the lungs
and liver. Histopathological analysis revealed a dose-
dependent lung inflammatory response characterized by
neutrophils and foamy alveolar macrophage accumulationand epithelioid granulomas formation. The accumulation of
GO in liver indicated that GO might mainly be eliminated by
liver secretion into the bile tract system, because little GOwas
observed in the kidney. These results suggest that GOmay not
be suitable for human use because its shape makes it very
difficult for the kidney to remove [68]. A similar study in mice
also demonstrated that GOwas cleared from the blood quickly
and accumulatedmainly in the liver and lungs, with the larger
sizes of GO (1e5 mm) accumulating in the lungs whereas
smaller sizes (110e500 nm) were retained by the liver [89]. In
addition, intratracheal injection of 50 mg GO in C57BL/6 mice
induced severe and persistent injuries in the lungs. Dispersion
of pristine graphene with the blocking copolymer Pluronic
greatly reduced the toxicity [90]. Another study also demon-
strated extensive pulmonary thromboembolism in Swissmale
mice only 15 minutes after intravenously administrating
250 mg/kg body weight GO [76]. However, GO purification via
several washings may eliminate the toxicological and in-
flammatory effects as no inflammation or granuloma forma-
tion was induced in female C57BL/6 mice following
intraperitoneal injection of 50 mg highly pure, colloidally sta-
ble, and evenly dispersed GO in physiologically relevant
aqueous buffers [24,91].
In addition to pulmonary inflammation and thromboem-
bolism, immune responses were detected in the lungs of
C57BL/6 mice after intravenous administration of 1 mg/kg
body weight of graphene nanosheets [92]. Graphene nano-
sheets triggered an increase in interleukin (IL)-33 and its sol-
uble receptor sST2 in the bronchoalveolar lavage fluid 1 day
following injection, and resulted in a Th2 immune response
consisting of neutrophilic influx and increases in IL-5 and IL-
13. Results using ST2e/e mice indicated that the site-specific
Th2 immune responses of graphene nanosheets were
dependent upon the IL-33/ST2 axis.
To investigate the potential adverse effects of GO on the
eye, Japanese white rabbits were injected intravitreally with
0.1 mg, 0.2 mg, or 0.3 mg of GO and monitored for up to 49
days. There was no clinical evidence of forocular changes and
GO had a negligible influence on both the intraocular pressure
and eyesight in treated animals as determined by slit lamp
biomicroscopy and indirect funduscopic examination [71]. GO
content decreased gradually in the eyes during the observa-
tion period, and histological examination at the conclusion of
the experiment observed a very small amount of residual GO
with no retinal abnormality in the GO-injected eyes. These
results suggest that intravitreal injection of up to 0.3 mg of GO
has no significant negative effects on the eyes [71].
Surface modifications can also modulate the toxicity of
graphene in vivo. A series of the in vivo pharmacokinetics,
biodistribution, and toxicology studies of graphene and
PEGylated graphene using three administration routes
(intravenous, intraperitoneal, and oral) have been performed
in BALB/c mice [25,93,94]. One hour after an intravenous in-
jection dose of 20 mg/kg, PEG-graphene nanosheets were
distributed in many different organs. Three days later, PEG-
graphene was found mainly in the reticuloendothelial sys-
tem, including the spleen and liver [94]. Toxicity studies of
PEG-graphene nanosheets revealed neither death nor signifi-
cant body weight drop in the mice during the 90-day treat-
ments. Blood biochemistry and hematology analysis did not
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including alanine aminotransferase, aspartate aminotrans-
ferase, and alkaline phosphatase. The ratio of albumin and
globulin, the urea levels in the blood, and all hematology
markers were also unchanged [94]. In addition, there was no
obvious organ damage except for a brown discoloration in the
liver and spleen due to the accumulation of PEG-graphene
nanosheets in the 1st 20 days [94]. Recently, Yang et al. [93]
investigated the biodistribution and potential toxicity of GO
and several PEGylated GO derivatives with different sizes and
surface coatings after oral and intraperitoneal administra-
tions to BALB/c mice at a dose of 4 mg/kg [93]. No obvious
tissue uptake was observed following oral administration,
indicating limited intestinal adsorption of these nano-
materials. By contrast, following intraperitoneal injection, the
researchers detected a much higher accumulation of PEG-GO
derivatives, but not GO, in the reticuloendothelial system,
including the liver and spleen. Similar to their previous study,
histological examination of organ sections and hematological
analysis revealed only insignificant changes to animals,
although the nanomaterials did persist in the mouse body
over 3 months [93]. These results suggest that the in vivo
behavior and toxicology of GFNs depend on the administra-
tion route.
Inhalation toxicity is a major concern for the production
and use of nanomaterials. Due to their similar aerodynamic
properties, the inhalation toxicity of graphene nanoplatelets
(average diameter of 5 mm) and nanoparticulate carbon black
(diameter of 10 nm) has been studied in C57BL/6 mice [59].
Mice were dosed with 50 mg/mouse by pharyngeal aspiration
or 5 mg/mouse by intrapleural injection, followed by lavaging
the lung and pleural space. Following a 24-hour exposure,
there was extensive recruitment of inflammatory cells (mac-
rophages and granulocytes) and proinflammatory cytokines
(e.g., monocyte chemoattractant protein-1, macrophage in-
flammatory protein-1R, IL-1b) into the lungs and pleural space
in mice treated with graphene as compared to the nano-
particulate carbon black group or its vehicle control [59]. His-
tological examination identified granulomatous lesions in the
bronchiole lumen and near the alveolar region, as well as
histiocytic aggregates in the parietal pleura in graphene-
treated mice, but not in the carbon black or control mice.
Furthermore, there was slower clearance of graphene nano-
platelets from the pleural space to the cranial mediastinal
lymph nodes as compared to nanoparticulate carbon black.
This study highlights the importance of particle shape on the
induction of adverse effects and suggests that it is critical to
consider the potential risks before introducing a new shape of
graphene. Another study compared the inhalation toxicity of
four carbon-based nanomaterials (MWCNTs, graphene,
graphite nanoplatelets, and nanoparticulate carbon black) in
male Wistar rats [95]. The rats were exposed head-nose to
atmospheres containing 0.1 mg/m3, 0.5 mg/m3, or 2.5 mg/m3
of MWCNT or 0.5 mg/m3, 2.5 mg/m3, or 10 mg/m3 of graphene,
graphite nanoplatelets, and nanoparticulate carbon black for
6 hours/day on 5 consecutive days. No adverse effects were
observed after inhalation exposure to graphite nanoplatelets
or nanoparticulate carbon black. By contrast, rats exposed to
2.5 mg/m3 MWCNT and graphene had increased numbers of
lymphocytes, polymorphonuclear neutrophil, and cytokines,increased activities of g-glutamyl-transpeptidase, LDH, and
alkaline phosphatase in bronchoalveolar lavage fluid, and
microgranulomas were observed in their lungs, with MWCNT
producing the stronger responses [95]. However, the toxicity
was not correlated to the volumetric load of these nano-
materials, suggesting that a complex interaction of several
parameters may be involved in the inhalation toxicity of these
materials.
Further in vivo toxicological studies exposed Caenorhabditis
elegans to GFNs [96e98]. C. elegans is a free-living, transparent
nematodewith a length of about 1mm. Exposure to 250 mg/mL
graphite nanoplatelets, consisting of 3e60 graphene layers
with a lateral size of 1e10 mm, resulted in no detectable
toxicity as measured by longevity and reproductive capacity
[97]. By contrast, prolonged oral administration at doses of
0.5e100 mg/mL GO damaged both primary (intestine) and
secondary (neuron and reproductive organ) targeted organs,
and the change was closely correlated with ROS production
[96]. GO was translocated into intestinal cells with the loss of
microvilli and distributed to surrounding mitochondria. GO
also caused a prolonged defecation cycle and alterations in
the expression of genes responsible for intestinal develop-
ment and defecation behavior. These results indicate that
long-term exposure to GO may place environmental organ-
isms at risk due to the combinational effects of oxidative
stress, enhanced permeability of the biological barrier, and
prolonged defecation behavior [96].
A dual-path chemical mechanismwas developed for the C.
elegans model, involving the overproduction of hydroxyl rad-
icals and the formation of oxidizing cytochrome c in-
termediates, to account for GO’s toxic properties under both
normal and stress conditions [98]. Under normal conditions,
10 mg/mL and 20 mg/mL of PEGylated poly-L-lysine GO triggered
a moderate ROS elevation but had no influence on worm
behavior or reproductive ability.When thewormswere placed
under conditions of oxidative stress and heat stress, exposure
to 5 mg/mL and 20 mg/mL PEGylated poly-L-lysine GO signifi-
cantly decreased nematode lifespan. When exposed to stress,
the cytochrome complex could be translocated from the
mitochondria to the cytoplasm, providing an opportunity for
direct contact with PEGylated poly-L-lysine GO [98]. Thus,
under pathophysiological conditions, GO-included toxicity
may involve the cytochrome c/H2O2 systems.5. Summary
The applications of GFNs have developed rapidly in the past
few years. Thus, a comprehensive understanding of the
interaction of GFNs with living systems and their adverse ef-
fects in vitro and in vivo are essential for further development
and safe use of graphene-based nanomaterials.
The majority of current literature agree that unmodified
graphene, GO and rGO are cytotoxic and/or genotoxic.
Although surface modified GFNs with ultra-small sizes,
excellent dispersibility, and stability in physiological envi-
ronments are often less toxic, there are inconsistencies be-
tween studies. Dose is one of the most important factors and
some researchers believe that low doses of GFNs may be safe;
sometimes they can even serve as enhancers of cell
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GFNs, such as the particle size, particulate state, surface
functional groups, and oxygen content/surface charges may
significantly affect their toxicity in biological systems. The
Organization for Economic Co-operation and Development
has concluded that the current testing approaches are
generally acceptable for nanomaterials, although modifica-
tions may be necessary for some test guidelines. The current
results indicate that genotoxicity assays may serve as a sen-
sitive approach for evaluating the adverse effects of GFNs,
and there is a demand for more data on genotoxicity testing,
because only a few published studies are in the literature.
Moreover, the presence of contaminants during the process-
ing of nanomaterials may also contribute to their adverse
effects. Although the mechanisms for their toxicity have
not been determined definitively, ROS is the most widely
recognized mechanism for GFN-induced toxicity in living
systems.
It is difficult to compare the toxicological effects of GFNs
between different studies due to the diversity in the sizes,
shapes, surfaces, and the fabrication of GFNs. For example,
different production methods cause different amounts of ox-
ygen to be bound to the surface of GFNs, which has proven to
be correlated with their toxicity towards cells and other living
systems [99]. There is a need for standardizing the terminol-
ogy, the fabrication of GFNs, and the validation of toxicolog-
ical methodologies. Standardization will provide necessary
information to researchers for better understanding the
physicochemical characteristics and the potential toxicolog-
ical effects in cells and animals, thus facilitating the practical
applications of these promising new nanomaterials in
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